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Comparison Between the Two Most
Used Diagnostic Criteria
Enrique Gomez Pomar 1*, Vanessa A. Concina 1, Aaron Samide 2, Philip M. Westgate 3 and
Henrietta S. Bada 1
1Division of Neonatology, Department of Pediatrics, University of Kentucky, Lexington, KY, United States, 2Department of
Pediatrics, Johns Hopkins All Children’s Hospital in Florida, St. Petersburg, FL, United States, 3Department of Biostatistics,
College of Public Health, University of Kentucky, Lexington, KY, United States
Objectives: To compare the Shennan’s and the consensus definition of
Bronchopulmonary Dysplasia (BPD) from the National Institutes of Health (NIH)
workshop and analyze specific risk factors associated with each definition.
Study design: Retrospective analysis of records of 274 infants admitted to a level IV
intensive care unit. Infants were classified as having BPD or no BPD by both definitions.
Differences in incidence and risk factors were analyzed. Statistical methods included
descriptive statistics, comparative tests, and marginal logistic regression modeling.
Results: The estimated difference in prevalence was 32% [95% CI: (26%, 37%),
(p < 0.0001)] between both criteria. The prevalence of BPD was 80% higher based on
the NIH criteria [RR = 1.80; 95% CI: (1.58, 2.06)]. Infants with no BPD by the Shennan
definition were breathing room air with or without positive or continuous pressure support
and were most likely to be discharged home on oxygen [OR = 4.47, 95% CI: (1.20,
16.61), p = 0.03]. Gestational age, birth weight, and 1-min Apgar score predicted BPD
by both definitions. Chorioamnionitis increased the risk of BPD by the Shennan definition
but was associated with lower risk by the NIH criteria. IUGR was associated with BPD
by the Shennan definition and with severe BPD by the NIH criteria.
Conclusion: Compared to the Shennan’s definition, the NIH consensus identified 80%
more infants with BPD and is a better predictor of oxygen requirement at discharge. Until
a new better criteria is develop, the NIH consensus definition should be used across
centers.
Keywords: chronic lung disease, BPD definition, premature, infants, bronchopulmonary dysplasia
INTRODUCTION
Bronchopulmonary dysplasia (BPD) is a term coined in 1967 to describe the clinical, pathologic
and radiographic features of preterm infants that require prolonged mechanical ventilation and
oxygen support (1). Preterm infants initially developed hyaline membrane disease and, despite the
high mortality rate, survived, but with severe mucosal, alveolar, and vascular changes due to the
prolonged exposure to high ventilator pressures and oxygen (1). As survival improved and new
advances in neonatal care were introduced, infants developed a different BPD, sometimes described
Gomez Pomar et al. NICHD vs. Shennan Criteria for BDP Definition
as a “new BPD,” which was characterized by an arrest in alveolar
development, less fibrosis, and a more uniform inflammation
(2, 3). In spite of the advances in the identification of factors that
are related to the development of BPD (4–10) and its prevention
(11, 12), BPD continues to be the most prevalent sequelae among
survivors following preterm birth (13, 14).
Defining BPD has been a topic of debate ever since the
initial criteria was proposed (3, 15–17). The original definition
included infants with oxygen requirement for 28 days with
associated radiographic changes (3, 17). Shennan et al. found
that oxygen requirement for the first 28 days provided a poor
positive predictive value for abnormal pulmonary findings as the
gestational age decreases. However, oxygen need at 36 weeks
Post-Menstrual Age (PMA) predicted abnormal pulmonary
outcomes better (3, 18). Therefore, oxygen requirement at 36
weeks PMA became the criteria for BPD definition in infants
born with birth weight (BW) <1,500 g (18). This is the definition
adopted by the Vermont-Oxford Network (19). However, the
continued use of oxygen for the first 28 days is influenced by
variation in clinical practices or protocols established at different
centers (3, 14).
In lieu of the original definition, a new definition was
proposed in 2001 as summarized by Jobe and Bancalari (3)
from the discussions in a workshop organized by the National
Institutes of Health (NIH). The definition of BPD differed
according to gestational age (GA). For those born at GA < 32
weeks, BPD referred to requirement of oxygen support (>21%)
for at least 28 days and a subsequent assessment at 36 weeks
PMA or discharge, whichever comes first. In those born with GA
> 32 weeks, BPD referred to the requirement of supplemental
oxygen <21% for at least 28 days and a subsequent assessment
at 56 days post-natal age or discharge, whichever comes first.
At the time of this assessment, those infants with no oxygen
requirement were classified as having mild BPD. Moderate BPD
was diagnosed in those requiring <30% oxygen and severe BPD
in those with a need for positive pressure ventilation/continuous
positive pressure (PPV/CPAP) and/or oxygen requirement≥30%
(3). With the use of the new severity-based definition, 68% of
infants admitted to centers from the Neonatal Research Network
were diagnosed to have BPD (27% mild, 23% moderate and
18% severe) during the years 2003–2007 (17). This definition
has since been adopted by the Eunice Kennedy Shriver National
Institute of Child Health and Development Neonatal Research
Network (3).
Using one definition or another can cause differences in the
incidence of BPD. In 2005, a study by Ehrenkranz et al. found that
44% of infants were diagnosed with BPD as defined by oxygen use
at 36 weeks PMA compared to 77% by using the NIH definition
(20). These findings were confirmed by Poindexter et al. who
found a 10% difference in the no BPD diagnosis between both
definitions (21). Despite this, different centers across the country,
as well as several multicenter trials and quality improvement
initiatives, use either definition in characterizing infants with or
without BPD (13, 20, 22–25). This study aimed to compare the
BPD definitions by NIH and Shennan in an effort to understand
how the differences between these two definitions would have
an impact in clinical practice and follow up after discharge. As a
secondary objective, we evaluated the factors that would predict
BPD by each definition.
PATIENTS AND METHODS
This retrospective study was conducted with a cohort of
premature infants admitted to a level IV Neonatal Intensive
Care Unit (NICU) during 2013, 2014, and 2015. This study was
approved by the Institutional Review Board. Electronic medical
records of the study infants were reviewed and pertinent variables
were entered into the password protected data base (REDCap
software, Version 6.13.2 @ 2016 Vanderbilt University, Nashville
TN) (26). Inclusion criteria were admission to the NICU, GA
≤30 weeks, and survival up to 36 weeks PMA. Exclusion criteria
included GA > 30 weeks, presence of significant congenital
anomalies, or death before 36 weeks PMA.
Prenatal factors, such as use of antenatal steroids, maternal
chorioamnionitis, intrauterine growth restriction, preeclampsia
and prolonged rupture of membranes were noted. Other
variables recorded were BW, GA, inborn/outborn status, gender,
Apgar scores at 1 and 5min, mode of delivery, surfactant
administration and length of stay in days. Infants who survived at
36 weeks PMA were categorized as BPD or No BPD based on the
Shennan andNIH criteria. The BPD outcome of interest was need
for oxygen at discharge or death after 36 weeks PMA, whichever
comes first.
Statistical Analysis
Descriptive statistics included determination of either means
± standard deviations or medians with interquartile ranges
(IQR) for continuous variables and frequencies and percentages
for categorical variables. McNemar’s test was used to compare
incidences between the two different BPD criteria, and
generalized estimating equations (GEE) (27) were used
to estimate the difference and ratio of these incidences.
Comparisons of BPD and No BPD classifications for each
definition separately were conducted utilizing two-sample
t-tests, Wilcoxon tests, and either chi-square or Fisher’s exact
tests. Comparisons of Shennan vs. NIH criteria with respect to
the impacts of potential predictors on the odds of BPD were
made using GEE and marginal logistic regression modeling.
Furthermore, with respect to oxygen requirement at 28 days,
we calculated the C statistic, an estimate for the area under the
receiver-operating characteristic curve and thus the predictive
accuracy of this variable, and the optimal cutoff value based
on the minimum Euclidean distance and maximum sum of
sensitivity and specificity. Additionally, we determined the
sensitivities, specificities, positive predictive values, negative
predictive values, and the proportion correctly classified based
on these optimal cutoffs. Tests were two-sided, with statistical
significance defined as p < 0.05. Analyses were conducted in SAS
version 9.4 (SAS Institute, Cary, N.C.).
RESULTS
A total of 247 infants fulfilled our inclusion criteria. Of these,
38 infants were evaluated at discharge and 209 at 36 weeks GA.
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Mean GA was 27.0 ± 1.7 weeks, mean BW was 975 ± 268 g,
58% were males and 29% of the infants were transferred to our
facility. Sixty-eight percent and 12% of the infants were born after
a full course and partial course of antenatal steroids, respectively.
Delivery was by cesarean section in 72% of the infants. The
median (range) Apgar scores were 4 (2, 6) and 6 (4, 8) at 1 and
5min, respectively. Surfactant in the delivery room was given to
88% of the infants; of these, 31% received a second dose and 7%
received a third dose. The average length of stay was 87± 43 days.
Regarding BPD classification in our cohort, 39% (97 infants)
were found to require oxygen at 36 weeks and were classified
to have BPD by the Shennan definition, compared to 71% (175
infants) using the NIH definition. Of those with BPD by NIH
criteria, 17% (42), 4% (11), and 49% (122 infants) were classified
as mild, moderate and severe BPD, respectively. Additionally,
53.9% of those with mild BPD by the NIH definition were
classified as not having BPD using the Shennan definition.
Table 1 depicts the classification of infants by both definitions.
The difference in BPD incidence between criteria was significant
(p < 0.0001). Specifically, the estimated difference in incidence
was 32% [95% CI: (26%, 37%)], such that the incidence was
estimated to be 80% higher based on the NIH criteria [RR= 1.80;
95% CI: (1.58, 2.06)].
Of those classified as no BPD by the Shennan’s definition,
78 infants were identified as having BPD by the NIH definition.
Of these, 42, 2, and 34 infants were classified as mild, moderate
and severe BPD, respectively. Further analysis showed that 34/78
(43.6%) were receiving some form of positive pressure ventilation
(41% on CPAP, 1.3% on NIPPV, and 1.3% on a mechanical
ventilator) and the remaining 2/78 (2.6%) were on nasal cannula.
In order to evaluate how maternal, perinatal, and infant
factors are predictive of BPD, we analyzed their association with
each BPD definition (Table 2). An increase of 1 week in GA
[Shennan-OR = 0.56, 95% CI: (0.46, 0.69), p < 0.0001; NIH-
OR = 0.44, 95% CI: (0.34, 0.56), p < 0.0001], an increase of 1
in Apgar score at 1-min [Shennan-OR = 0.88, 95% CI: (0.79,
0.99), p= 0.04; NIH-OR= 0.78, 95%CI: (0.69, 0.89), p= 0.0001],
and an increase of 100 gm in BW [Shennan-OR = 0.69, 95% CI:
(0.60, 0.78), p < 0.0001; NIH-OR = 0.63, 95% CI: (0.55, 0.71),
p < 0.0001] were associated with significant decreases in odds of
BPD by either definition; however, the decrease is significantly
greater when using the NIH definition (p ≤ 0.04).
Furthermore, having chorioamnionitis was estimated to
increase the odds of BPD based on the Shennan’s definition
[OR = 1.36, 95% CI: (0.58, 3.19), p = 0.47], but decreased the
odds based on the NIH definition [OR = 0.66, 95% CI: (0.28,
1.58), p = 0.35]. These disparate results between definitions
(p = 0.04) correlates with the controversy that chorioamnionitis
is a risk factor for BPD for some authors but not all (10, 17). Of
note, IUGRwas significantly associated with BPD by the Shennan
definition and with severe BPD by NIH criteria.
Of all the factors that were associated with BPD, oxygen use at
28 days post-natal age was the best predictor for the development
of BPD by either definition. Oxygen use at 28 days had a
comparable sensitivity, 95 and 99%, respectively, as predictor
of BPD by NIH and the Shennan criteria. However, the use of
oxygen at 28 days had a better specificity, positive predictive value
and higher proportion of correctly classified when defining BPD
using NIH criteria. Oxygen use at 28 days had the best negative
predictive value (99%) for BPD by Shennan’s definition. Further,
we estimated that the optimal cutoff for oxygen requirement at
28 days were FiO2 of 0.22 and 0.24, respectively, as predictor of
BPD by NIH and Shennan’s criteria (Table 3).
We also assessed the need for oxygen at discharge or death
before discharge after 36 weeks PMA. Of those with no BPD, 11
and 3% of the infants by Shennan and NIH criteria, respectively,
were discharged home on oxygen or died before discharge.
Infants who were classified as having no BPD by Shennan were
more likely to be discharged home on oxygen compared to those
classified as not having BPD by the NIH definition [OR = 4.47,
95% CI: (1.20, 16.61), p= 0.03].
DISCUSSION
The incidence of BPD using the NIH criteria is 80% higher
when compared to the Shennan’s definition with an estimated
difference of 32%. This difference is consistent with other
publications (20, 21). Associated with either definition are the
risk factors: BW, GA, male sex, IUGR, low Apgar scores,
intubation in the delivery room, and additional surfactant doses.
Infants classified as not having BPD by the Shennan criteria are
more likely to go home on oxygen compared to those classified as
no BPD by the NIH criteria.
Throughout the years, the characteristics and treatment of
infants who developed BPD have remarkably changed since it
was initially described by Northway (1). The widespread uses
of antenatal steroids and surfactant administration have reduced
the risk of BPD in the at-risk population (28). Nevertheless,
BPD continues to be a major cause of morbidity and mortality
in the extremely low birth weight (ELBW) infants (24, 28, 29).
Because studies in the past several years have drawn attention
to the associated unfavorable pulmonary or functional outcomes
related to BPD, prediction models or scoring systems have
been proposed to identify those at risk (4, 6–9, 15, 30)1. Most
prediction models have included similar perinatal risk factors
that we noted in our study (8, 31). In our cohort as well as in
other studies, oxygen use at 28 days post-natal age was the best
predictor of BPD by either definition (18), more specifically any
oxygen use when using the NIH criteria. This observation has the
potential to be included when developing BPD predictor models
(18, 32).
The definition of BPD in a preterm infant carries an important
influence in predicting future health issues or interventions (24,
29, 33–36). By Shennan’s criteria 50% of infants receiving oxygen
at 36 weeks PMA were destined to have abnormal pulmonary
outcomes as measured by re-hospitalization secondary to
respiratory infection or disease like asthma or the need for
pulmonary medications, such as bronchodilators or steroids (18).
Similarly, by using the NIH criteria, Ehrenkranz et al. reported
an increasing incidence of adverse pulmonary outcome as BPD
becomes more severe (20).
1Palta 1998 Evaluation of Criteria for CLD.pdf.
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Sheenan BPD 0 0 9 88 97
Shennan BPD negative 72 42 2 34 150
Total 72 42 11 122 247














Gestational age (weeks)a 26.2 ± 1.6 27.6 ± 1.4 26.4 ± 1.6 26.2 ± 1.3 26.9 ± 1.4 28.2 ± 1.2
Birth weight (grams)a 842 ± 228 1,061 ± 257 871 ± 232 893 ± 202 956 ± 231 1,173 ± 246
Malea 65 (67%) 79 (53%) 78 (64%) 10 (91%) 23 (55%) 33 (46%)
Femalea 32 (33%) 71 (47%) 44 (36%) 1 (9%) 19 (45%) 39 (54%)
ANTENATAL STEROIDS
Complete 65 (69%) 95 (67%) 77 (65%) 7 (70%) 30 (77%) 46 (69%)
Partial 10 (11%) 19 (13%) 28 (24%) 0 (0%) 4 (10%) 11 (16%)
None 19 (20%) 27 (19%) 14 (12%) 3 (30%) 5 (13%) 10 (15%)
Intrauterine growth restrictionc 13 (14%) 8 (5%) 16 (13%) 1 (9%) 2 (5%) 2 (3%)
Preeclampsia 19 (20%) 30 (20%) 30 (25%) 0 (0%) 8 (19%) 11 (15%)
Prolonged premature rupture of
membranes
34 (35%) 41 (27%) 37 (30%) 6 (55%) 9 (21%) 23 (32%)
Chorioamnionitisb 11 (11%) 13 (9%) 13 (11%) 0 (0%) 2 (5%) 9 (13%)
Cesarean section 70 (72%) 108 (72%) 94 (77%) 8 (73%) 29 (69%) 47 (66%)
Vaginal delivery 27 (28%) 41(28%) 28 (23%) 3 (27%) 13 (31%) 24 (34%)
Inborn 65 (67%) 108 (72%) 81 (66%) 8 (77%) 31 (74%) 53 (74%)
Outborn 32 (33%) 42 (28%) 41 (34%) 3 (23%) 11 (26%) 19 (26%)
Apgar score 1 minb 3 (2, 5) 4 (2, 6) 3 (1, 5) 4 (3, 7) 5 (2, 6) 5 (3, 7)
Apgar score 5min 6 (4, 7) 7 (5, 8) 6 (4, 7) 5 (3, 8) 7 (5, 8) 7 (6, 8)
SURFACTANTa
1st dose at delivery 93 (96%) 124 (83%) 119 (98%) 9 (82%) 36 (86%) 53 (74%)
2nd dose 46 (49%) 29 (20%) 56 (47%) 2 (18%) 8 (20%) 9 (13%)
3rd dose 13 (13%) 4 (3%) 14 (11%) 1 (9%) 2 (5%) 0 (0%)
28 days oxygen usea 95 (99%) 79 (53%) 116 (96%) 10 (91%) 40 (95%) 8 (11%)
Home on oxygen or death before
dischargea
87 (90%) 17 (11%) 90 (74%) 9 (82%) 3 (7%) 2 (3%)
Length of stay (days)a 99 (79, 115) 71 (57, 85) 94 (79, 108) 75 (65, 105) 74 (65, 88) 58 (49, 75)
Mean ± SD, median (IQR).
ap < 0.05 with respect to the comparison of BPD and No BPD based on the given condition.
bp < 0.05 for the comparison of Shennan vs. NIH with respect to the impact the given variable has on the odds of BPD.
cp = 0.04 for the comparison of BPD vs. No BPD and p = 0.02 for severe BPD vs. No BPD by NIH.
The prevalence of BPD has been used as an index of quality
of care when comparing different centers (23). Specifically, it
is used as an estimate of center-specific therapeutic strategy-
effectiveness as well as a gauge of when management protocols
need to be updated (37–39). Of concern is that in our cohort, 80%
more infants were identified as having BPD by NIH compared to
Shennan’s definition which fails to identify infants on respiratory
support at 36 weeks GA as having BPD. Contrary to expectation,
the inclusion of need for respiratory support in the definition
has not been widely accepted across major centers (23, 32, 40).
By not correctly classifying these infants, it becomes harder for
clinicians and researchers to evaluate the real impact of BPD
on long term pulmonary outcomes (11, 25, 37). Those with no
BPD by the Shennan definition were four times more likely to go
home on oxygen compared to those with no BPD byNIH criteria.
A measure that is highly predictive at 36 weeks PMA of the
need for oxygen on discharge is relevant to assist families, even
prior to discharge, to access resources and medical services that
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TABLE 3 | Oxygen use at 28 days of life.
Definition Sn Sp PPV NPV PCC C statistic
ANY OXYGEN USE
NIH 0.95 0.89 0.95 0.89 0.93 0.92
VON 0.99 0.47 0.55 0.99 0.67 0.73
Definition Cutoff Sn Sp PPV NPV PCC C statistic
LOWEST OXYGEN LEVEL
NIH 22 0.759 1.000 1.000 0.612 0.825 0.880
VON 24 0.879 0.783 0.727 0.908 0.821 0.885
will be needed for weeks or months after NICU hospitalization
(24, 34, 36, 39).
Bronchopulmonary dysplasia has also been associated with
changes in the pulmonary vasculature of affected infants
like, decreased in the cross-sectional vascular bed, increased
pulmonary vascular tone and reactivity (41). Therefore, infants
that are diagnosed with BPD have an increased risk of developing
pulmonary artery hypertension (PH) which adds significantly to
the morbidity and mortality of these infants (42). The presence
of IUGR and SGA have been identify as an additional risk
factor for the development of PH (31, 41, 43). However, the
evaluation of PH in infants with BPD is highly variable as
well as its management (31, 42). Even though none of the
current definitions assist with stratification of risk for BPD/PH,
a standardize use of a definition would aid in the identification of
infants at risk for PH.
A third definition of BPD, the “physiologic definition,” was
proposed in 2003 (44). Infants that required positive pressure
and oxygen ≥0.3 at 36 weeks PMA were classified as BPD, those
requiring FiO2 <0.3 required an oxygen reduction test for up to 2
weeks based on oxygen saturations (44). However, this definition
has not gained popularity. Compared to the definition of oxygen
requirements at 36 weeks PMA, the “physiologic definition” took
in consideration the use of positive pressure and showed a 10%
reduction in the incidence of BPD with less variability among
centers (45).
In summary, BPD incidence differs depending upon the
definition used. Furthermore, if the definition is based on
oxygen requirement alone, being in room air at 36 weeks is
not necessarily a predictor of not requiring oxygen at discharge.
Lacking the capability into determination of alveolar and
pulmonary vascular pathology, we strongly urge for a consensus
in defining BPD from a clinical perspective, if BPD is to serve as
one of clinical outcome measures across centers. Indeed, a sound
recommendation on which definition to use will standardized the
incidence of BPD as alluded to by Bancalari et al. (25). Also the
definition is to be such that it will not only identify those infants
with BPD but will also be a predictor of the pulmonary care needs
at discharge and follow-up.
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